Related Experiment Video
Updated: May 26, 2026
Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
Published on: June 29, 2022
Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe
Anna Sliwa1, Gabriela Plucinska, Joanna Bednarczyk
1Laboratory of Epileptogenesis, The Nencki Institute of Experimental Biology, Polish Academy of Sciences, 3 Pasteur St., 02-093 Warsaw, Poland.
Abstract:
Approximately 30% of all epilepsy cases are acquired. At present there is no effective strategy to stop epilepsy development after the precipitating insult. Recent data from experimental models pointed to the mTOR pathway, which can be potently inhibited by rapamycin. However, data on the antiepileptic and antiepileptogenic properties of rapamycin are conflicting. Therefore, we tested whether rapamycin post-treatment influences epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy in rats. Animals were treated with rapamycin (6mg/kg) or vehicle daily for 2 wks, beginning 24h after stimulation. Sham-operated animals were treated with rapamycin or vehicle but were not stimulated. Animals were video-EEG monitored to detect spontaneous seizures. Animals were sacrificed 4 wks later and brains were collected for Timm staining. There were no significant differences in the number of stimulated rats developing epilepsy; latency to first spontaneous seizure; number of seizures, or seizure frequency in epileptic animals. The area occupied by mossy fibers was significantly increased in stimulated vs. sham-operated animals but was not different in animals treated with rapamycin vs. vehicle. Collectively, our data suggest that the antiepileptic or antiepileptogenic action of rapamycin is not a universal phenomenon and might be limited to certain experimental models or experimental conditions.
Insights
Rapamycin, a drug targeting the mTOR pathway, did not prevent epilepsy development or reduce seizures in a rat model of temporal lobe epilepsy. These findings suggest rapamycin
Area of Science:
- Neuroscience
- Pharmacology
- Epilepsy Research
Background:
- Acquired epilepsy accounts for 30% of cases, with no current strategy to halt epileptogenesis post-insult.
- The mTOR pathway, inhibitable by rapamycin, is implicated in epilepsy, but its antiepileptogenic effects remain controversial.
Purpose of the Study:
- To investigate the efficacy of rapamycin post-treatment in preventing epileptogenesis in a rat model of temporal lobe epilepsy.
- To determine if rapamycin influences seizure development and mossy fiber sprouting after amygdala stimulation.
Main Methods:
- Rats underwent amygdala stimulation and received daily rapamycin or vehicle treatment for two weeks, starting 24 hours post-stimulation.
- Video-electroencephalography (EEG) monitored spontaneous seizures.
- Brain tissue was analyzed for mossy fiber gliosis using Timm staining four weeks after stimulation.
Main Results:
- No significant differences were observed in epilepsy development, seizure latency, or seizure frequency between rapamycin-treated and vehicle-treated groups.
- Amygdala stimulation led to increased mossy fiber sprouting, but rapamycin treatment did not alter this effect.
Conclusions:
- Rapamycin post-treatment demonstrated no significant antiepileptic or antiepileptogenic effects in this specific rat model of temporal lobe epilepsy.
- The study suggests that the therapeutic potential of rapamycin in epilepsy may be context-dependent and not universally applicable.
